Statistically Significant Reduction in Viral Load Confirmed in Clinical Trial
Primary Endpoint Achieved
In the highest dose group, there was an 88.94% reduction in viral load (P<0.0001)
About S-337395
About the Phase 2 Human Challenge Trial
About RSV infection
About UBE Corporation
References
1. Press release on December 10, 2018.
2. Press release on February 28, 2022.
3. Press release on October 24, 2024.
4. U.S. Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV). Accessed January 23, 2025. Available at https://www.cdc.gov/rsv/causes/index.html.
5. Drysdale SB, Broadbent L. Respiratory syncytial virus (RSV): over 60 years of research but still so many unanswered questions. Ther Adv Infect Dis. 2023;10:20499361231159991. doi:10.1177/20499361231159991.
6. U.S. Centers for Disease Control and Prevention. Surveillance of RSV. Accessed January 23, 2025. Available at https://www.cdc.gov/rsv/php/surveillance/index.html.
7. Miloje Savic et al. Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis. Influenza Other Respir Viruses. 2022 Nov 11;17(1):e13031. doi: 10.1111/irv.13031
Forward-Looking Statements
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
U.S. Media: ShionogiCommunications@shionogi.com
SEU Press Office: pressoffice@shionogi.eu